cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alaunos Therapeutics Inc
15 own
5 watching
Current Price
$0.13
$0
(1.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
110.69M
52-Week High
52-Week High
2.10000
52-Week Low
52-Week Low
0.11000
Average Volume
Average Volume
0.93M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization110.69M
icon52-Week High2.10000
icon52-Week Low0.11000
iconAverage Volume0.93M
iconDividend Yield--
iconP/E Ratio--
What does the Alaunos Therapeutics Inc do?
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Read More
How much money does Alaunos Therapeutics Inc make?
News & Events about Alaunos Therapeutics Inc.
Globe Newswire
5 months ago
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral ...
Ticker Report
6 months ago
Alaunos Therapeutics, Inc. (NASDAQ:TCRT Get Rating) Investment analysts at Jefferies Financial Group issued their FY2027 earnings estimates for Alaunos Therapeutics in a research note issued on Tuesday, March 7th. Jefferies Financial Group analyst C. Howerton forecasts that the ...
Globe Newswire
8 months ago
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR TCR discovery platformIncreasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting common hotspot ...
Globe Newswire
10 months ago
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately24,228,719 shares of its common stock for gross ...
Globe Newswire
10 months ago
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Alaunos Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Alaunos Therapeutics Inc shares?
plus_minus_icon
How can I buy Alaunos Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Alaunos Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alaunos Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Alaunos Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Alaunos Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alaunos Therapeutics Inc?
plus_minus_icon
What percentage is Alaunos Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alaunos Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.13
$0
(1.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00